214 related articles for article (PubMed ID: 25638249)
1. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.
Johnson JA; Hamadeh IS; Langaee TY
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638249
[No Abstract] [Full Text] [Related]
2. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
Goetz MP; Sun JX; Suman VJ; Silva GO; Perou CM; Nakamura Y; Cox NJ; Stephens PJ; Miller VA; Ross JS; Chen D; Safgren SL; Kuffel MJ; Ames MM; Kalari KR; Gomez HL; Gonzalez-Angulo AM; Burgues O; Brauch HB; Ingle JN; Ratain MJ; Yelensky R
J Natl Cancer Inst; 2014 Dec; 107(2):. PubMed ID: 25490892
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
[No Abstract] [Full Text] [Related]
5. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype and tamoxifen response.
Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
[No Abstract] [Full Text] [Related]
7. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
[TBL] [Abstract][Full Text] [Related]
8. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
Hayes DF; Stearns V; Rae J; Flockhart D;
J Natl Cancer Inst; 2008 May; 100(9):610-3. PubMed ID: 18445818
[No Abstract] [Full Text] [Related]
9. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO; Gelderblom H; Van Schaik RH; Vletter-Bogaartz JM; Van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2014 Jan; 143(1):171-9. PubMed ID: 24265036
[TBL] [Abstract][Full Text] [Related]
11. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
Higgins MJ; Stearns V
Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
[No Abstract] [Full Text] [Related]
12. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
Thota K; Prasad K; Basaveswara Rao MV
Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
[TBL] [Abstract][Full Text] [Related]
13. Update on CYP2D6 and Tamoxifen.
Goetz MP
Clin Adv Hematol Oncol; 2013 Mar; 11(3):178-80. PubMed ID: 23598986
[No Abstract] [Full Text] [Related]
14. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
15. Update on CYP2D6 and its impact on tamoxifen therapy.
Goetz MP
Clin Adv Hematol Oncol; 2010 Aug; 8(8):536-8. PubMed ID: 20966889
[No Abstract] [Full Text] [Related]
16. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Dec; 118(3):531-8. PubMed ID: 19597703
[TBL] [Abstract][Full Text] [Related]
17. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.
Lash TL; Rosenberg CL
J Clin Oncol; 2010 Mar; 28(8):1273-5. PubMed ID: 20124162
[No Abstract] [Full Text] [Related]
18.
Wei X; Cai J; Zhuang J; Zheng B; Sui Y; Zhang G; Lin Y; Sun H
Pharmacogenomics; 2020 Jan; 21(1):43-53. PubMed ID: 31769341
[No Abstract] [Full Text] [Related]
19. Pharmacogenetics of breast cancer therapies.
Hertz DL; McLeod HL; Hoskins JM
Breast; 2009 Oct; 18 Suppl 3():S59-63. PubMed ID: 19914545
[TBL] [Abstract][Full Text] [Related]
20. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]